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Initial reports indicate a high incidence of acute kidney injury (AKI) in Coronavirus Disease
2019 (COVID-19), but more data are required to clarify if COVID-19 is an independent risk
factor for AKI and how COVID-19–associated AKI may differ from AKI due to other causes.
We therefore sought to study the relationship between COVID-19, AKI, and outcomes in a
retrospective cohort of patients admitted to 2 acute hospitals in Derby, United Kingdom.
Methods and findings
We extracted electronic data from 4,759 hospitalised patients who were tested for COVID-
19 between 5 March 2020 and 12 May 2020. The data were linked to electronic patient rec-
ords and laboratory information management systems. The primary outcome was AKI, and
secondary outcomes included in-hospital mortality, need for ventilatory support, intensive
care unit (ICU) admission, and length of stay. As compared to the COVID-19–negative
group (n = 3,374), COVID-19 patients (n = 1,161) were older (72.1 ± 16.1 versus 65.3 ± 20.4
years, p < 0.001), had a greater proportion of men (56.6% versus 44.9%, p < 0.001), greater
proportion of Asian ethnicity (8.3% versus 4.0%, p < 0.001), and lower proportion of white
ethnicity (75.5% versus 82.5%, p < 0.001). AKI developed in 304 (26.2%) COVID-19–posi-
tive patients (COVID-19 AKI) and 420 (12.4%) COVID-19–negative patients (AKI controls).
COVID-19 patients aged 65 to 84 years (odds ratio [OR] 1.67, 95% confidence interval [CI]
1.11 to 2.50), needing mechanical ventilation (OR 8.74, 95% CI 5.27 to 14.77), having
congestive cardiac failure (OR 1.72, 95% CI 1.18 to 2.50), chronic liver disease (OR 3.43,
95% CI 1.17 to 10.00), and chronic kidney disease (CKD) (OR 2.81, 95% CI 1.97 to 4.01)
had higher odds for developing AKI. Mortality was higher in COVID-19 AKI versus COVID-
19 patients without AKI (60.5% versus 27.4%, p < 0.001), and AKI was an independent pre-
dictor of mortality (OR 3.27, 95% CI 2.39 to 4.48). Compared with AKI controls, COVID-19
AKI was observed in a higher proportion of men (58.9% versus 51%, p = 0.04) and lower
proportion with white ethnicity (74.7% versus 86.9%, p = 0.003); was more frequently asso-
ciated with cerebrovascular disease (11.8% versus 6.0%, p = 0.006), chronic lung disease
(28.0% versus 19.3%, p = 0.007), diabetes (24.7% versus 17.9%, p = 0.03), and CKD
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(34.2% versus 20.0%, p < 0.001); and was more likely to be hospital acquired (61.2% versus
46.4%, p < 0.001). Mortality was higher in the COVID-19 AKI as compared to the control
AKI group (60.5% versus 27.6%, p < 0.001). In multivariable analysis, AKI patients aged 65
to 84 years, (OR 3.08, 95% CI 1.77 to 5.35) and�85 years of age (OR 3.54, 95% CI 1.87 to
6.70), peak AKI stage 2 (OR 1.74, 95% CI 1.05 to 2.90), AKI stage 3 (OR 2.01, 95% CI 1.13
to 3.57), and COVID-19 (OR 3.80, 95% CI 2.62 to 5.51) had higher odds of death. Limita-
tions of the study include retrospective design, lack of urinalysis data, and low ethnic diver-
sity of the region.
Conclusions
We observed a high incidence of AKI in patients with COVID-19 that was associated with a
3-fold higher odds of death than COVID-19 without AKI and a 4-fold higher odds of death
than AKI due to other causes. These data indicate that patients with COVID-19 should be




Why was this study done?
• Recent reports have suggested that some patients with Coronavirus Disease 2019
(COVID-19) develop acute kidney injury (AKI).
• There is a need to better understand risk factors for AKI in patients with COVID-19.
• It is also unclear if AKI in patients with COVID-19 differs from AKI due to other
causes.
What did the researchers do and find?
• In this study, we examined risk factors for AKI in patients with COVID-19 and also
compared AKI in COVID-19 with AKI due to other causes.
• We found that males and patients of nonwhite ethnicity as well as those with comorbidi-
ties were at increased risk of developing AKI in COVID-19.
• AKI was associated with a 3-fold increase in mortality in COVID-19 patients.
• Patients with COVID-19 and AKI had higher mortality (60.5% versus 27.6%) than
patients with AKI due to other causes, and COVID-19 was an independent predictor of
mortality associated with an almost 4-fold odds of death.
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What do these findings mean?
• COVID-19 frequently causes AKI, and when it does, it is associated with a higher mor-
tality than COVID-19 without AKI or AKI due to other causes.
• Patients with COVID-19 should be monitored for early evidence of AKI so that preven-
tive measures can be taken to avoid AKI.
Introduction
The rapid progression of the global pandemic caused by the novel coronavirus, Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has resulted in an urgent need to under-
stand the pathogenesis and variable clinical features of Coronavirus Disease 2019 (COVID-
19). Lung involvement in the form of viral pneumonia, inflammatory infiltrates, and endothe-
lial damage resulting in respiratory failure has been well documented and has been the focus
of attention, but other organs including the kidneys are also affected in COVID-19 [1,2]. In
the previous SARS epidemic, the reported incidence of acute kidney injury (AKI) was 6.7%
with a high mortality of over 90% [3]. However, SARS-CoV-2 is a novel betacoronavirus
belonging to the sarbecovirus subgenus of Coronaviridae family, and its effect on the kidneys
is not yet fully understood. There have been reports of nephrology services being overwhelmed
with new consults and the need for renal replacement therapy (RRT), which increased 18-fold
during the COVID-19 pandemic [4]. In initial reports, AKI incidence in people with COVID-
19 has ranged from 5% to 29% with substantial variation between centres, possibly due to dif-
ferences in population demographics and risk factors for AKI [1,2,5–9]. Some reports on a
small number of patients suggest that SARS-CoV-2 may have a specific effect on the kidneys,
but it is not yet clear to what extent COVID-19 increases the risk of AKI or how AKI associ-
ated with COVID-19 may differ from AKI due to other causes [10,11].
In this study, we investigated the incidence and risk factors associated with AKI in patients
admitted with COVID-19 and the impact of AKI on survival in 2 large acute hospitals in the
UK. Further, to investigate possible unique features of AKI due to COVID-19, we studied
patients with AKI from any cause and compared the clinical features and outcomes of those
with and without COVID-19.
Methods
Study design and ethical approval
This was an investigator-initiated, multicentre, retrospective cohort study. The study protocol
was assessed by the Research and Development Department of University Hospitals of Derby
and Burton (UHDB) National Health Service (NHS) Trust and approved by the Health
Research Authority and Wales Research Ethics Committee, and the study was registered in the
National Library of Medicine website (www.clinicaltrials.gov) with registration number
NCT04407156. The protocol is available as S1 Text. The research involved analysis of anon-
ymised data routinely collected in the course of normal care and written informed consent was
waived due to the nature of the study and pandemic nature of the disease. Data were analysed
and interpreted by the authors who reviewed the manuscript and confirm the accuracy and
completeness of the data and adherence to the protocol. The study was conducted according
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to the principles expressed in the Declaration of Helsinki, and the results are reported accord-
ing to the strengthening the reporting of observational studies in epidemiology (STROBE)
guidelines (S1 Checklist).
Participants and setting
This retrospective study was performed in UHDB NHS Foundation Trust. The Trust is com-
prised of 5 hospitals, of which 2 are acute hospitals with accident and emergency departments,
serving a population of approximately 1.5 million people in Derbyshire and Staffordshire in
the UK. We included all adult patients who were suspected of having COVID-19 infection and
were admitted to the 2 acute hospitals between 5 March 2020 and 12 May 2020. During the
study period, almost all elective admissions were cancelled. Clinical outcomes were collected
until 13 May 2020, which was the final date of follow-up.
Study design and procedures
All patients suspected of having COVID-19 infection and admitted to either of the 2 acute hos-
pitals underwent nasal and pharyngeal swabbing. SARS-CoV-2 was detected using real-time
reverse transcriptase polymerase chain reaction (RT-PCR), which was performed in the desig-
nated regional laboratory at Sheffield Teaching Hospitals NHS Foundation Trust. Antibody
testing was not used to define COVID-19–positive cases. Patients were retested after 48 hours
of a negative test, if there was high clinical suspicion of COVID-19 illness or if the swabbing
process was judged to be inadequate. The criteria for COVID-19 testing in the UK included all
patients who needed hospital admission because of clinical or radiological evidence of pneu-
monia or acute respiratory distress syndrome or influenza-like illness. Patients admitted with
these presentations were tested regardless of travel history. We excluded the following patients:
under the age of 18 years, not admitted to the hospital as per the above criteria, patients whose
swab results were awaited, and those needing chronic maintenance haemodialysis or perito-
neal dialysis. The microbiology database containing the results of nasal and pharyngeal swabs
was linked to laboratory information management system (LIMS), hospital’s electronic patient
records (EPRs), electronic prescribing and medicine administration (EPMA) dataset, and criti-
cal care minimum dataset (CCMD). The hospital’s LIMS has incorporated a nationally agreed
(NHS England) AKI detection algorithm that generates automated real-time electronic alerts
for AKI based on Kidney Disease Improving Global Outcomes (KDIGO) serum creatinine cri-
teria with baseline creatinine defined as either the lowest creatinine available within 7 days or a
median of serum creatinine values within 8 to 365 days [12,13]. The laboratory system then
sends the test result using existing information technology (IT) connections to EPR. We
extracted the first, the peak, and the last AKI stages along with corresponding dates of the test
results. We also extracted intensive care unit (ICU) admission and discharge date and outcome
disposition at discharge along with details of organ support from the CCMD. CCMD is used
to collect daily data in critical care regarding reason for admission, organ support, length of
stay, and outcome at discharge from critical care. During the study period, all RRTs were deliv-
ered as continuous renal replacement therapy (CRRT) except for 1 patient, who underwent
slow low efficiency dialysis (SLED) treatment. We extracted data for patient demographics,
comorbidities, and other diagnoses during hospital stay, which were based on codes from the
International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM)
and clinical outcomes that included length of stay, discharge method, and discharge destina-
tion. We extracted start and end date of any angiotensin converting enzyme inhibitors (ACEI)
or angiotensin receptor blocker (ARB) prescription during inpatient stay. We included only
the last admission for patients with multiple admissions during the observation period to
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reduce selection bias. Patients who were not yet discharged from the hospital at the end of the
study were recorded as alive. Charlson comorbidity index (CCI) was calculated from comor-
bidities that were extracted from the hospital EPR. Ethnicity was collected by the hospital self-
reporting mechanism. Patients admitted during the study period who presented with or devel-
oped AKI but were SARS-CoV-2 PCR–negative were treated as controls.
Study outcomes
The primary outcome was incident AKI. The secondary outcomes were in-hospital all-cause
mortality, need for ventilatory support, ICU admission, and length of stay.
Study definitions
Patients were suspected of having COVID-19 if the symptoms included fever greater than or
equal to 37.8˚C and at least 1 of the following symptoms with acute onset: persistent cough
(with or without sputum), hoarseness, nasal discharge or congestion, shortness of breath, sore
throat, wheezing, and sneezing. The national criteria for screening did not include loss of taste
or anosmia at the time of the study. AKI was identified using modified KDIGO definition of
AKI as identified by NHS England’s algorithm [14]. The algorithm compares the current mea-
sured serum creatinine from an individual patient against the baseline creatinine value defined
as either the lowest in the last 7 days or a median of values from the preceding 8 to 365 days
depending on availability of previous results stored in LIMS in real time. Urine output is not
used in generating the AKI alerts in the AKI algorithm. Hospital-acquired AKI (h-AKI) was
defined as AKI developing after 24 hours of hospital admission.
Statistical analysis
The study followed the analysis plan as stated in the protocol (S1 Text) and can also be found
at dx.doi.org/10.17504/protocols.io.bimskc6e. Descriptive statistical analysis was performed,
and continuous variables are reported as mean with standard deviation (SD) and compared
using a t test. Categorical variables are reported as proportion and percentages and were com-
pared using chi-squared test or Fisher’s exact test. Multiple imputation was not performed for
missing data due to the very low proportion of missing data. If a patient’s EPR or EPMA did
not include information on comorbidity or use of ACEI or ARB, it was assumed that this
information was absent.
We compared patients with confirmed COVID-19, referred to as “COVID-19 AKI,” to
those who did not develop AKI during the hospital stay, referred to as “COVID-19 controls.”
We also compared the characteristics of patients with COVID-19 who died versus those who
survived. Further, we compared COVID-19 AKI patients with AKI patients who did not have
COVID-19, referred to as “AKI controls” in the manuscript. Unadjusted associations between
continuous and categorical variables in the groups were assessed by t test or the chi-squared
test as appropriate. Comorbidities studied included myocardial infarction (MI), congestive
cardiac failure (CCF), peripheral vascular disease (PVD), cerebrovascular disease (CVD),
dementia, chronic lung disease, connective tissue disorder (CTD), diabetes with complica-
tions, paraplegia, chronic kidney disease (CKD), chronic liver disease, and cancer. Multivari-
able logistic regression analysis was used to investigate associations of baseline patient and
clinical characteristics with outcomes defined as incident AKI or mortality. Age was not nor-
mally distributed and was log transformed. However, a Box–Tidwell procedure indicated a
nonlinear relationship of log-transformed age with outcomes. We attempted several other
transformations of age, but none was able to produce a linear relation to the logit of the depen-
dent variable. We therefore adopted the approach of categorising age into 3 groups based on
PLOS MEDICINE AKI in COVID
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003406 October 30, 2020 5 / 16
the biological plausibility of COVID-19 affecting certain age-groups differently. Variables that
were associated with outcomes in univariable analyses were included in the models. Results
are presented as odds ratios (ORs) and 95% confidence intervals (CIs). To verify the robustness
of our findings, we performed sensitivity analyses using CCI instead of individual comorbidi-
ties. In the first, we analysed the risk factors associated with AKI in COVID-19, and in the sec-
ond, we assessed the factors associated with mortality in AKI patients. All tests were 2-tailed,
and p< 0.05 was considered significant. Analysis was performed on IBM SPSS Statistics for
Mac, Version 24.0 (IBM Corp, UK).
Results
During the period from 5 March 2020 to 12 May 2020, 4,759 patients, who were tested for
COVID-19, had 5,932 admissions to the UHDB. We excluded the following as per the exclu-
sion criteria: 261 patients under the age of 18 years, 32 admissions in 21 patients on various
forms of maintenance dialysis, and 4 duplicate records. There were 1,100 initial admissions
with subsequent readmissions during the study period. In the final analysis, we included 4,535
admissions in 4,535 patients, of whom 1,161 were SARS-CoV-2 PCR–positive and 3,374 were
SARS-CoV-2 PCR–negative. Data on comorbidities were missing in 14 patients, and ethnicity
was missing in 7 patients. The overall incidence of AKI was 16%; AKI developed in 304
patients with COVID-19 (26.2%) and 420 patients without COVID-19 (12.4%) (Fig 1).
Factors associated with AKI in COVID-19
Demographic, comorbidity, treatment, and outcome variables for patients with COVID-19 are
shown in Table 1. As compared to COVID-19 controls, patients with COVID-19 AKI had a
higher mean age (74.9 ± 12.8 years versus 71.1 ± 17.0 years, p = 0.003), but there was no differ-
ence in the age-groups. COVID-19 AKI patients had a higher prevalence of comorbidities: MI
(13.8% versus 9.0%, p = 0.021), CCF (26.6% versus 14.7%, p< 0.001), CKD (34.2% versus
14.0%, p< 0.001), and chronic liver disease (3.0% versus 0.9%, p = 0.024). COVID-19 AKI
patients were also more likely to require ICU admission (21.1% versus 3.7%, p< 0.001),
mechanical ventilation (16.4% versus 3.6%, p< 0.001), evidenced a higher mortality (60.5%
versus 27.4%, p< 0.001), and had a longer length of stay (9.3 ± 10.8 versus 7.1 ± 10.3 days,
p = 0.003) than COVID-19 patients without AKI. AKI developed in 61.7% of COVID-19–posi-
tive patients who needed mechanical ventilation as compared to 23.5% of COVID-19–positive
patients who did not need mechanical ventilation (p< 0.001).
Multivariable logistic regression analysis was performed using age, gender, ethnicity, resi-
dence in care home, use of ACEI/ARB, need for mechanical ventilation, and comorbidities as
independent variables, selected on the basis of significant associations in univariable analyses.
The analysis identified the following independent risk factors for AKI in patients with
COVID-19: age 65 to 84 years (OR 1.67, 95% CI 1.11, 2.50), age�85 years (OR 1.66, 95% CI
1.01, 2.71), CCF (OR 1.72, 95% CI 1.18, 2.50), chronic liver disease (OR 3.43, 95% CI 1.17,
10.00), CKD (OR 2.81, 95% CI 1.97, 4.01), and needing mechanical ventilation (OR 8.74, 95%
CI 5.17, 14.77) (Table 2).
Factors associated with mortality in COVID-19
We compared demographic and clinical characteristics between survivors and non-survivors
with COVID-19 (S1 Table). As compared to COVID-19 survivors, patients who died were
older (68.9 ± 17.2 years versus 77.7 ± 12.0 years, p< 0.001), more likely to be male (53.1% ver-
sus 62.8%, p = 0.02) and care home residents (13.9% versus 19.1%, p = 0.02), more likely to
require mechanical ventilation (5.4% versus 9.8%, p = 0.006), and had more comorbidities: MI
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(7.1% versus 15.8%, p< 0.001), CCF (12.7% versus 27.0%, p< 0.001), PVD (3.1% versus 10.3%,
p< 0.001), dementia (9.3% versus 22.7%, p< 0.001), chronic lung disease (23.2% versus 33.2%,
p< 0.001), diabetes with complications (19.1% versus 27.0%, p = 0.002), chronic liver disease
(0.7% versus 2.9%, p< 0.01), CKD (12% versus 32.2%, p< 0.001), and cancer (5.4% versus
9.8%, p = 0.006). COVID-19 patients who died were also more likely to have developed AKI
(16.2% versus 43.9%, p< 0.001). We performed multivariable logistic regression analysis to
identify independent predictors of mortality in COVID-19. Higher age-group (age-group 65 to
84 years: OR 3.47, 95% CI 2.27, 5.3; age-group�85 years: OR 4.33, 95% CI 2.62,7.16), male sex
Fig 1. Study flowchart showing the number of participants involved at each stage of the study. AKI, acute kidney injury; COVID-19, Coronavirus
Disease 2019.
https://doi.org/10.1371/journal.pmed.1003406.g001
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(OR 1.4, 95% CI 1.05, 1.86), PVD (OR 2.44, 95% CI 1.35, 4.42), dementia (OR 2.27, 95% CI
1.49, 3.44), chronic liver disease (OR 4.37, 95% CI 1.27, 15.1), CKD (OR 1.7, 95% CI 1.18, 2.44),
Table 1. Patient characteristics in groups with and without AKI according to COVID-19 status.
COVID-19–positive COVID-19–negative p-value p-value
No AKI (A) AKI (B) AKI (C) B vs. C A vs. B
DEMOGRAPHICS
Number of patients 857 (73.8) 304 (26.2) 420 (12.4)
Age in yearsϮ 71.1 ± 17.0 74.9 ± 12.8 73.1 ± 16.7 0.125 0.003
Age-group (years) 18–64 253 (29.5) 68 (22.4) 102 (24.3) 0.588 0.057
65–84 405 (47.3) 158 (52) 202 (48.1)
85+ 199 (23.2) 78 (25.7) 116 (27.6)
Gender Male 478 (55.8) 179 (58.9) 214 (51) 0.041 0.381
Ethnicity White 649 (75.7) 227 (74.7) 365 (86.9) 0.003 0.443
Asian 77 (9) 19 (6.3) 12 (2.9)
Black 13 (1.5) 8 (2.6) 6 (1.4)
Not stated 103 (12) 43 (14.1) 32 (7.6)
Care home residence 135 (15.8) 48 (15.8) 66 (15.7) 1.000 1.000
COMORBIDITIES
Myocardial infarction 77 (9) 42 (13.8) 40 (9.5) 0.076 0.021
Congestive cardiac failure 126 (14.7) 81 (26.6) 89 (21.2) 0.092 <0.001
Peripheral vascular disease 44 (5.1) 22 (7.2) 21 (5) 0.265 0.194
Cerebrovascular disease 81 (9.5) 36 (11.8) 25 (6) 0.006 0.267
Dementia 119 (13.9) 45 (14.8) 49 (11.7) 0.220 0.702
Chronic lung disease 226 (26.4) 85 (28) 81 (19.3) 0.007 0.598
Connective tissue disorder 57 (6.7) 17 (5.6) 29 (6.9) 0.538 0.586
Diabetes with complications 180 (21) 75 (24.7) 75 (17.9) 0.032 0.116
Paraplegia 22 (2.6) 7 (2.3) 6 (1.4) 0.407 1.000
Chronic kidney disease 120 (14) 104 (34.2) 84 (20) <0.001 <0.001
Chronic liver disease 8 (0.9) 9 (3) 18 (4.3) 0.429 0.022
Cancer 70 (8.2) 32 (10.5) 48 (11.4) 0.721 0.238
AKI CHARACTERISTICS
Peak AKI Stage 1 175 (57.6) 251 (59.8) 0.115
Stage 2 56 (18.4) 93 (22.1)
Stage 3 73 (24) 76 (18.1)
Hospital AKI 186 (61.2) 195 (46.4) <0.001
AKI stage progression 68 (22.4) 59 (14) 0.004
TREATMENT
ACEI or ARB use¥ 124 (14.5) 34 (11.2) 66 (15.7) 0.101 0.173
Need for intensive care 32 (3.7) 64 (21.1) 43 (10.2) <0.001 <0.001
Mechanical ventilation 31 (3.6) 50 (16.4) 32 (7.6) <0.001 <0.001
Renal replacement therapy 23 (7.6) 9 (2.1) <0.001
Renal support (days) 2.4 ± 5.7 3.4 ± 7.1 0.502
OUTCOMES
Length of stay (days)Ϯ 7.1 ± 10.3 9.3 ± 10.8 8.9 ± 15.0 0.761 0.003
Mortality 235 (27.4) 184 (60.5) 116 (27.6) <0.001 <0.001
¥ Angiotensin converting enzyme or angiotensin receptor blocker.
Ϯ Data are presented as mean ± standard deviation or number (percent).
AKI, acute kidney injury; COVID-19, Coronavirus Disease 2019.
https://doi.org/10.1371/journal.pmed.1003406.t001
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cancer (OR 3.02, 95% CI 1.88, 4.85), need for mechanical ventilation (OR 3.02, 95% CI 1.87,
5.73), and development of AKI (OR 3.27, 95% CI 2.39, 5.73) remained independent predictors
of mortality, but the association of use of ACEI or ARB in COVID-19 with all-cause mortality
was no longer statistically significant (OR 0.79, 95% CI 0.52, 1.19) (Table 3).
Comparison of AKI in patients with COVID-19 and non-COVID-19
disease
We compared characteristics of the 304 patients with COVID-19 AKI with the group of 420
patients who developed AKI but were COVID-19–negative, referred to as “AKI controls,”
admitted during the same period (Table 1). There was no difference in mean age or the age-
groups between the 2 groups. As compared to AKI controls, COVID-19 AKI evidenced a
greater proportion of men (58.9% versus 51.0%, p = 0.041), lower proportion with white ethnic-
ity (74.7% versus 86.9%, p = 0.003), more h-AKI (61.2% versus 46.4%, p< 0.001), greater pro-
portion needing ICU (21.1% versus 10.2%, p< 0.001), and mechanical ventilation (16.4%
versus 7.6%, p< 0.001). COVID-19 AKI patients also evidenced a greater proportion with
Table 2. Multivariable logistic regression to identify risk factors for AKI in COVID-19 disease.
Odds ratios p-value
DEMOGRAPHICS
Age-group 18–64 1 (Ref)
65–84 1.67 (1.11, 2.5) 0.013
85+ 1.66 (1.01, 2.71) 0.045
Gender Male 0.99 (0.74, 1.33) 0.955
Ethnicity White 1 (Ref)
Asian 0.89 (0.49, 1.6) 0.687
Black 2.29 (0.88, 6.02) 0.091
Not stated 1.14 (0.74, 1.77) 0.541
Care home residence 1.01 (0.66, 1.55) 0.962
COMORBIDITIES
Myocardial infarction 1.18 (0.74, 1.86) 0.486
Congestive cardiac failure 1.72 (1.18, 2.5) <0.001
Peripheral vascular disease 1.05 (0.58, 1.9) 0.860
Cerebrovascular disease 1.04 (0.63, 1.73) 0.865
Dementia 0.87 (0.56, 1.36) 0.539
Chronic lung disease 0.95 (0.68, 1.32) 0.756
Connective tissue disorder 0.69 (0.38, 1.28) 0.242
Diabetes with complications 1.06 (0.75, 1.5) 0.748
Paraplegia 0.69 (0.26, 1.87) 0.470
Chronic kidney disease 2.81 (1.97, 4.01) <0.001
Chronic liver disease 3.43 (1.17, 10) 0.024
Cancer 1.37 (0.85, 2.22) 0.198
TREATMENT
ACEI or ARB use¥ 0.69 (0.45, 1.08) 0.108
Mechanical ventilation 8.74 (5.17, 14.77) <0.001
¥ Angiotensin converting enzyme or angiotensin receptor blocker.
The model was statistically significant, χ2(4) = 148.1, p< 0.001, and Hosmer–Lemeshow test was not significant, p =
0.78.
AKI, acute kidney injury; COVID-19, Coronavirus Disease 2019.
https://doi.org/10.1371/journal.pmed.1003406.t002
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comorbidities: CVD (11.8% versus 6.0%, p = 0.006), chronic lung disease (28.0% versus 19.3%,
p = 0.007), diabetes with complication (24.7% versus 17.9%, p = 0.032), and CKD (34.2% versus
20.0%, p< 0.001). COVID-19 AKI patients were more likely than AKI controls to progress to
higher AKI stages (22.4% versus 14.0%, p = 0.004) and need RRT (7.6% versus 2.1%, p< 0.001),
but there was no difference in peak AKI stages or the length of stay between the 2 groups.
Factors associated with mortality in patients with AKI
Overall, we observed 300 deaths in patients with AKI (41.4%), 184 (60.5%) in the COVID-19
AKI group versus 116 (27.6%) in AKI controls (p< 0.001). In univariable analyses, other fac-
tors associated with mortality in patients with AKI included age, gender, comorbidities, use of
ACEI/ARB, ICU admission, mechanical ventilation, need for RRT, peak AKI stages, h-AKI,
Table 3. Multivariable logistic regression to identify risk factors for mortality in COVID-19 disease.
Odds ratios p-value
DEMOGRAPHICS
Age-group COVID-19 18–64 1 (Ref)
65–84 3.47 (2.27, 5.3) <0.001
85+ 4.33 (2.62, 7.16) <0.001
Gender Male 1.39 (1.05, 1.86) 0.020
Ethnicity White 1 (Ref)
Asian 1.20 (0.68, 2.14) 0.527
Black 0.97 (0.31, 3.05) 0.965
Mixed 2.59 (0.39, 17.19) 0.323
Others 2.01 (0.6, 6.75) 0.261
Not stated 1.02 (0.66, 1.58) 0.940
Care home residence 0.86 (0.58, 1.3) 0.480
COMORBIDITIES
Myocardial infarction 1.47 (0.93, 2.31) 0.096
Congestive cardiac failure 1.38 (0.95, 1.99) 0.090
Peripheral vascular disease 2.44 (1.35, 4.42) <0.001
Cerebrovascular disease 0.75 (0.45, 1.25) 0.271
Dementia 2.27 (1.49, 3.44) <0.001
Chronic lung disease 1.27 (0.92, 1.74) 0.146
Connective tissue disorder 1.21 (0.71, 2.07) 0.487
Diabetes with complications 1.15 (0.82, 1.61) 0.411
Paraplegia 1.35 (0.55, 3.34) 0.513
Chronic kidney disease 1.69 (1.18, 2.44) <0.001
Chronic liver disease 4.37 (1.27, 15.1) 0.020
Cancer 3.02 (1.88, 4.85) <0.001
TREATMENT
ACEI or ARB use¥ 0.79 (0.52, 1.19) 0.252
Mechanical ventilation 3.28 (1.87, 5.73) <0.001
OUTCOME
AKI 3.27 (2.39, 4.48) <0.001
¥ Angiotensin converting enzyme or angiotensin receptor blocker.
The model was statistically significant, χ2(4) = 292.2, p< 0.001, and Hosmer–Lemeshow test was not significant,
p = 0.50.
AKI, acute kidney injury; COVID-19, Coronavirus Disease 2019.
https://doi.org/10.1371/journal.pmed.1003406.t003
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and progression of AKI stages (S2 Table). In multivariable logistic regression analysis, AKI
patients in the 65 to 84 years age-group, (OR 3.08, 95% CI 1.77, 5.35) and�85 years (OR 3.54,
95% CI 1.87, 6.70), peak AKI stage 2 (OR 1.74, 95% CI 1.05, 2.90) and stage 3 (OR 2.01, 95%
CI 1.13, 3.57), and progression of AKI to higher stages (OR 1.85, 95% CI 1.04, 3.31) had higher
odds of death (Table 4). Amongst comorbidities, CKD was not associated with increased odds
of death (OR 1.31, 95% CI 0.83, 2.08), but dementia (OR 2.17, 95% CI 1.19, 3.97), paraplegia
Table 4. Multivariable logistic regression to identify risk factors for mortality in patients with AKI.
Odds ratios p-value
DEMOGRAPHICS
Age-group 18–64 1 (Ref)
65–84 3.08 (1.77, 5.35) <0.001
85+ 3.54 (1.87, 6.7) <0.001
Gender Male 1.27 (0.88, 1.82) 0.201
Ethnicity White 1 (Ref)
Asian 1.49 (0.62, 3.58) 0.375
Black 2.77 (0.75, 10.24) 0.128
Not stated 1.52 (0.85, 2.73) 0.157
Care home residence 0.79 (0.45, 1.4) 0.432
COMORBIDITIES
Myocardial infarction 1.29 (0.69, 2.38) 0.432
Congestive cardiac failure 2.61 (1.64, 4.15) <0.001
Peripheral vascular disease 1.14 (0.54, 2.44) 0.728
Cerebrovascular disease 0.62 (0.32, 1.23) 0.172
Dementia 2.17 (1.19, 3.97) 0.012
Chronic lung disease 1.39 (0.91, 2.16) 0.131
Connective tissue disorder 1.44 (0.69, 2.97) 0.330
Diabetes with complications 0.89 (0.56, 1.39) 0.597
Paraplegia 9.95 (1.98, 49.94) 0.005
Chronic kidney disease 1.31 (0.83, 2.08) 0.250
Chronic liver disease 4.65 (1.72, 12.58) <0.001
Cancer 2.49 (1.43, 4.38) <0.001
COVID-19 STATUS
COVID-19–positive 3.79 (2.62, 5.51) <0.001
AKI CHARACTERISTICS
Peak AKI Stage 1 1 (Ref)
Stage 2 1.74 (1.05, 2.9) 0.032
Stage 3 2.01 (1.13, 3.57) 0.017
Hospital AKI 1.26 (0.86, 1.86) 0.238
AKI stage progression 1.85 (1.04, 3.31) 0.037
Renal replacement therapy 1.61 (0.62, 4.23) 0.331
TREATMENT
ACEI or ARB use¥ 0.48 (0.27, 0.85) 0.012
Mechanical ventilation 1.52 (0.81, 2.87) 0.194
¥ Angiotensin converting enzyme or angiotensin receptor blocker.
The model was statistically significant, χ2(4) = 228.0, p< 0.001, and Hosmer–Lemeshow test was not significant,
p = 0.59.
AKI, acute kidney injury; COVID-19, Coronavirus Disease 2019.
https://doi.org/10.1371/journal.pmed.1003406.t004
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(OR 9.95, 95% CI 1.98, 49.94), chronic liver disease (OR 4.64, 95% CI 1.72, 12.58), and cancer
(OR 2.50, 95% CI 1.43, 4.38) were associated with higher odds of death. AKI patients who had
COVID-19 had higher odds of death than COVID-19–negative patients with AKI (OR 3.8,
95% CI 2.62, 5.51). Patients who were received ACEI/ARB had lower odds of death (OR 0.48,
95% CI 0.27, 0.85).
Sensitivity analysis using CCI instead of individual comorbidities showed similar findings.
In both analyses, increasing CCI was an independent risk factor for higher mortality (S3 and
S4 Tables).
Discussion
In this retrospective, multicentre study, we found a high incidence of AKI affecting more than
a quarter of hospitalised patients with COVID-19. Independent predictors of AKI included
age, CCF, CKD, and chronic liver disease along with mechanical ventilation. The impact of
AKI on outcomes in the context of COVID-19 was demonstrated by the finding that AKI was
independently associated with 3-fold higher odds of death. Furthermore, by comparing AKI in
patients with and without COVID-19, we observed that AKI associated with COVID-19 was
independently associated with an almost 4-fold higher odds of death than AKI associated with
other acute illnesses.
Risk factors for AKI in COVID-19
We found the incidence of AKI in COVID-19 patients was more than double the incidence of
AKI in non-COVID-19 patients. The incidence of AKI in COVID-19 in our study is similar to
that reported from the United States of America (22.2% to 36%) but much higher than that
reported from China (5.1% to 10.5%) [1,2,6,7,15,16]. The variation in the incidence of AKI in
COVID-19 in different countries or regions may be explained in part by variable inclusion cri-
teria (intensive care and all hospital admissions) and also the varying demographic characteris-
tics and comorbidities of study populations. Our finding of greater age as a risk factor for AKI
is in keeping with 2 previous studies of AKI in COVID-19, though our study population was
older (mean age: 73 years) than in the study from the US (mean age: 69 years) and much older
than the Chinese cohort (mean age: 63 years) [5,15]. Though a higher proportion of men and
patients of Asian ethnicity with COVID-19 had AKI, we did not find that male sex or ethnicity
were independent risk factors for AKI. In contrast, studies from the US have reported men
and black ethnic groups at increased risk for developing AKI in COVID-19 [15,17]. Intensive
Care National Audit and Research Centre (ICNARC) has also reported lower proportion of
patients from Asian and black ethnicity discharged alive from ICU [18]. This apparent discrep-
ancy may be explained in part by the very low proportion of people of black ethnicity in the
local population resulting in reduced statistical power to study the impact of ethnicity.
We also confirmed that several comorbidities and the need for mechanical ventilation were
independent risk factors for AKI. Large variation has been reported in the prevalence of
comorbidities in patients with COVID-19 and AKI. For example, we observed that diabetes
was present in 25% of patients with COVID-19 and AKI, whereas the proportion with diabetes
in studies from the US has been reported as 41% to 47% and from China as 14% [5,6,15]. We
did not identify diabetes as risk factor for AKI or mortality in contrast to a study from the US
[15]. This may be because of the dominant effects of other comorbidities on mortality and war-
rants further investigation. We found prior CCF as well as CKD and liver disease to be strong
predictors of AKI in COVID-19, in keeping with data from another study which found that
the incidence of AKI was higher in patients presenting with baseline creatine above normal
(12 out of 101, 11.9% versus 24 out of 600, 4%) [5].
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Risk factors for mortality in COVID-19
Our findings confirmed that AKI is a strong independent risk factor for mortality in patients
with COVID-19, associated with a 3-fold increase in odds of in-hospital death. The impact of
AKI on mortality in COVID-19 has been reported in only 1 study to date [5]. Amongst 701
patients with COVID-19, AKI stages 2 and 3 were associated with increasing hazard ratios for
in-hospital death (stage 2: hazard ratio [HR] 3.53, 95% CI 1.50, 8.27 and stage 3: HR 4.72, 95%
CI 2.55, 8.75). We have also confirmed a strong association between older age and male sex
with mortality in COVID-19. Two large studies have reported that men and people from
Asian and black ethnicity were at markedly increased risk of in-hospital death from COVID-
19 [19,20]. Our findings confirm that previous CKD, dementia, chronic liver disease, and can-
cer are independent predictors of mortality [20]. Previous studies have indicated that SARS--
CoV-2 uses angiotensin converting enzyme 2 (ACE2) as a cell entry receptor, prompting some
investigators to suggest that treatment with ACEI or ARB may increase the risk of severe com-
plications associated with COVID-19 [21]. This has been questioned by others, and we found
no increase in mortality associated with ACEI or ARB treatment [22].
AKI in patients with COVID-19 versus non-COVID-19 disease
A unique aspect of this study is that we were able to compare AKI associated with COVID-19
with AKI due to other causes. We identified several differences between these groups including
higher proportion of men, patients from Asian and black ethnicity, and h-AKI. A greater pro-
portion of patients with COVID-19 AKI evidenced AKI stage progression and needed
mechanical ventilation and intensive care. We found that 7.6% of COVID-19 AKI patients
needed RRT in contrast to 2.1% in AKI controls. The need for RRT has ranged from 0.8% to
9% in China as compared to the US, where it has ranged from 14.3% to 55% [1,6,15,16]. The
aetiology of AKI in COVID-19 seems to be different than usual AKI in hospitalised patients. It
tends to occur late when patients are critically unwell, need mechanical ventilation, and vaso-
pressor support. However, there is also emerging evidence that kidneys are affected early in
COVID-19. Proteinuria and haematuria have been reported in 44% and 26.7% on admission,
respectively [5,23]. This suggests that there are a number of different causes of AKI in
COVID-19, and some mechanisms by which COVID-19 affects kidneys remain unclear.
Experimental studies in human kidney proximal tubular epithelial cells have shown persistent
infection with SARS-CoV-2 [24]. Further, transmission electron microscopy of kidneys in
patients who died of COVID-19 have demonstrated virus particles in cytoplasm of proximal
tubular cells, podocytes, and also in distal tubules [11]. These findings may suggest possible
mechanisms of proteinuria and AKI in COVID-19 patients. Recently, collapsing glomerulopa-
thy has been reported [10]. In spite of haematuria and proteinuria occurring early in the course
of illness, we found that AKI in COVID-19 tends to develop later than non-COVID-19 AKI.
This is in keeping with another study which reported that 62.7% of AKI developed after 24
hours, which in our study was defined as h-AKI. This may suggest that the causes of AKI in
COVID-19 may not be predominantly classical prerenal causes; direct effects of SARS-CoV-2
on the kidneys and the inflammatory effect of high cytokine levels (cytokine storm) may be
additional relevant factors. The practical implication of this observation is that patients with
COVID-19 who do not have AKI on admission should have daily monitoring to detect h-AKI
[25].
Risk factors for mortality in AKI
In all patients with AKI, we found increasing age, higher AKI stages, and AKI stage progres-
sion were associated with increasing odds of death. Increasing AKI stage has also been found
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to be associated with increased mortality in another study of COVID-19 with AKI. The
authors found mortality of 33.7% (34 out of 101) and had higher hazards of death (HR of 4.72
with AKI stage 3) [5]. In our study, the in-hospital mortality in AKI patients with COVID-19
was 60.5% as compared to 27.6% in AKI controls. In other studies of AKI in COVID-19, in-
hospital mortality ranged from 34.8% to 72% in the US and 16.1% to 86.4% in China
[5,6,15,17,23].
Importantly, we found that COVID-19 was an independent risk factor for mortality in
patients with AKI, associated with an almost 4-fold higher odds of in-hospital mortality. In the
analysis of all patients with AKI, use of an ACEI or ARB was associated with lower odds of
death, but as this was an observational study causality cannot be inferred. We did not find any
association between need for RRT and mortality in COVID-19 AKI; this may be due to a low
proportion of patients needing RRT in this study.
The retrospective and database nature of the study comes with some limitations. We did
not have access to urinalysis results, and hence it is difficult to deduce if COVID-19 affects kid-
neys earlier than the biochemical changes, which appear later. We were unable to obtain the
cause of AKI or the long-term outcomes due to a relatively short observation period, and this
may have generated survivor bias. Further studies with longer observation periods are required
to understand the long-term impact of COVID-19 on the kidneys. The East Midlands has a
low proportion of people of black and Asian ethnicity, and this study may have lacked statisti-
cal power to investigate the effect of COVID-19 in ethnic minority groups. In addition, we did
not have other laboratory investigations that may have helped to understand the severity of
COVID-19. Finally, we have tried to minimise the magnitude of unmeasured confounders by
having a COVID-19–negative AKI control, but, in an observational study, this can never be
completely eliminated.
In conclusion, we found high incidence of AKI in patients with COVID-19 that was inde-
pendently associated with greater age and comorbidities. AKI was associated with a 3-fold
higher odds of death in patients with COVID-19, and patients with COVID-19 and AKI were
at 4-fold higher odds of in-hospital death than those with AKI due to other causes. These data
provide robust evidence to support that patients with COVID-19 should be closely monitored
for the development of AKI and measures taken to prevent this, though further studies are
required to determine the most effective clinical approach.
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